Author

L. Tessarollo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:multiome· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Conte· 1 shared A. Das· 1 shared A. Olia· 1 shared B. Karim· 1 shared B. Luke· 1 shared D. A. Scheiblin· 1 shared F. Muecksch· 1 shared G.-Y. Chuang· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Conte

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

3'UTR-directed, kinase proximal mRNA decay inhibits C/EBPβ phosphorylation/activation to suppress senescence in tumor cells

J. Salotti, N. Asif, S. Basu, A. Das, M. Yang, B. Karim, K. Saylor, N. Martin, D. A. Scheiblin, S. Misra, B. Luke, T. Andresson, S. Lockett, L. Tessarollo, P. F. Johnson

This study identifies a mechanism where 3'UTR-directed mRNA decay inhibits C/EBPβ activation, suppressing senescence in tumor cells and promoting tumor progression.

bioRxiv · Mar 29, 2022Cancer Biology

Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants

J. Xu, K. Xu, S. K. Jung, A. Conte, J. Lieberman, F. Muecksch, J. C. C. Lorenzi, S. Park, Z. Wang, L. Tessarollo, T. Bylund, G.-Y. Chuang, A. Olia, I.-T. Teng, T. Zhou, , R. Casellas

This paper isolates and characterizes nanobodies from camelids and engineered mice that neutralize SARS-CoV-2 variants through conserved epitopes and multimeric avidity.

bioRxiv · Mar 4, 2021 · PreprintImmunology